Symposium 'Galectin Function and Therapeutics', which took place from September 17-19, 2012 in Boston, has had an important mission: to show the participants and the world where we stand with understanding galectins and theirfunctions and the direct applications of galectin management in practical medicine. This is a very complex and challenging issue. As is shown in Chapter 1, there are more than 3900 articles on galectins; on their structure and functions, published in academic literature since the middle of the 1990's. Most of these papers came from academia. As a result, we have a very advanced science on galectins, 15 of which were identified; on their chemical structure, interactions of galectins with their ligands of both carbohydrate and peptide nature, (alleged) mechanisms of their intracellular and intercellular operations, interception of various biochemical processes, their expression and regulatory effects of the expression, etc. Significant amounts of work have been done with experimental animals, including knockout gal(-/-) mice, as well on effects of galectins and their inhibitors on experimental pathologies in mice, rats, dogs, monkeys. In a few instances galectin inhibitors (galectin blockers) are being tested in human clinical trials, or will be tested soon. It all sounds very encouraging. However, a bird's eye view at these vastresearch areas reveals a somewhat troubling, though not an unusual pattern. An observant eye will notice that the galectin-related field of science, which is essentially biomedical science, consists of four largely disconnected areas. They are connected by only one feature--galectins themselves, which is the main object of attention for the researchers.
Edited by:
Anatole Klyosov,
Peter G. Traber
Imprint: Oxford University Press Inc
Country of Publication: United States
Volume: 1115
Dimensions:
Height: 230mm,
Width: 158mm,
Spine: 27mm
Weight: 776g
ISBN: 9780841228801
ISBN 10: 0841228809
Series: ACS Symposium Series
Pages: 456
Publication Date: 27 June 2013
Audience:
Professional and scholarly
,
Undergraduate
Format: Hardback
Publisher's Status: Active
"Contents Preface Overview 1. Galectins in Disease and Potential Therapeutic Approaches Anatole A. Klyosov and Peter G. Traber Galectin and Galectin Inhibitors: Structural Aspects 2. Low-Molecular Weight Inhibitors of Galectins Hakon Leffler and Ulf J. Nilsson 3. From Carbohydrate to Peptidomimetic Inhibitors of Galectins Kevin H. Mayo Galectin Extra- and Intra-Cellular Functions and Their Therapeutic Implications 4. Intracellular Galectins: Platforms for Assembly of Macromolecular Complexes John L. Wang, Kevin C. Haudek, Patricia G. Voss, Ronald J. Patterson, and Eric J. Arnoys 5. Galectins as Novel Regulators of Platelet Signaling and Function: Therapeutic Implications Gabriel A. Rabinovich and Mirta Schattner 6. Galectin-1 Cross-Linking of GM1 Ganglioside in Autoimmune Suppression Robert W. Ledeen, Gusheng Wu, David Bleich, Zi-Hua Lu, and Hans-Joachim Gabius 7. How To Build ""Lean and Mean"" Anti-Tumor T Cells: A Strategic View into the Anti-Carbohydrate Action of Fluorinated Glucosamine Analogs Charles J. Dimitroff 8. Post-Translational Modification of Galectin-3 and Its Role in Biological Function James C. Byrd, Nachman Mazurek, and Robert S. Bresalier Galectin Mechanisms and Therapeutic Approaches in Cancer 9. The Role of Galectin-3 in Malignant Melanoma Gordana Radosavljevic, Ivan Jovanovic, Jelena Pantic, Nada Pejnovic, Nebojsa Arsenijevic, Daniel K. Hsu, and Miodrag L. Lukic 10. Galectins as Novel Targets for the Treatment of Malignant Gliomas Herwig M. Strik and Matthias Ocker 11. Dynamic Tuning of Galectins and Their Binding Sites During Mammary Tumor Progression and Metastasis Joana T. de Oliveira and Fátima Gärtner 12. Galectin-3C: Human Lectin for Treatment of Cancer Gary A. Jarvis, Leonardo Mirandola, Yu Yuefei, Everardo Cobos, Maurizio Chiriva-Internati, and Constance M. John 13. Angiostatic Cancer Therapy by Targeting Galectins in the Tumor Vasculature Iris A. Schulkens, Arjan W. Griffioen, and Victor L. Thijssen 14. Galectins and Pathologies: Role of Galectin-3 in the Communication between Leukemia Cells and the Microenvironment Nora Heisterkamp, Fei Fei, and John Groffen 15. Translational Rational for the Clinical Development of OTX-008: A Novel Drug That Inhibits Galectin-1 Expression in Human Cancer Models Eric Raymond, Lucile Astrorgue-Xerri, Maria Serova, Maria Eugenia Riveiro, and Sandrine Faivre 16. Improving the Clinical Efficacy of Cancer Vaccines by Targeting Immune Suppression in Human Tumors Nathalie Demotte, Aristotelis Antonopoulos, Jean-François Baurain, Grégoire Wieërs, Nicolas Van Baren, and Pierre van der Bruggen 17. Targeting Galectin-3 Unveils the Complexity of Multiple Myeloma: A Sweet Context Leonardo Mirandola, Yuefei Yu, Constance M. John, Marjorie Jenkins, Everardo Cobos, and Maurizio Chiriva-Internati 18. Galectins in the Blood Circulation: Potential Therapeutic Targets of Cancer Metastasis Carrie A. Duckworth and Lu-Gang Yu Galectin Mechanisms and Therapeutic Approaches in Inflammation and Fibrosis 19. A Therapeutic Role for Galectins in Acute Inflammation? Dianne Cooper 20. Galectins in Immune and Inflammatory Diseases: Insights from Experiments with Galectin Deficient Mice Daniel K. Hsu, Ri-Yao Yang, Agnes Fermin, and Fu-Tong Liu 21. Autoimmune Disorders in Galectin-3 Deficient Mice Vladislav Volarevic and Miodrag L. Lukic 22. Galectin-3: A Central Regulator of Chronic Inflammation and Tissue Fibrosis Neil C. Henderson, Alison C. Mackinnon, Claire Rooney, and Tariq Sethi 23. The Role of Galectin-3 in Stellate Cell Activation and Liver Fibrosis Joy X. Jiang, Xiangling Chen, Hiroo Fukada, Dan K. Hsu, Fu-tong Liu, and Natalie J. Török 24. Galectin-3 Mediated Cardiovascular Fibrogenesis: An Important Cause of Heart Failure and Cardiovascular Mortality Wouter C. Meijers and Rudolf A. de Boer 25. Mucins and Galectin-3 in Ocular Surface Health and Disease Jerome Mauris and Pablo Argüeso 26. Role of Galectins in Wound Healing Noorjahan Panjwani, Ph.D. Editors' Biographies Indexes Author Index Subject Index"
Anatole Klyosov and Peter Traber are associated with Galactin Therapeutics, Inc., in Norcross, Georgia.
